Clinical Case Report

Isolated neurosarcoidosis mimicking multifocal meningiomas: a diagnosis pitfall

A case report

Kun Wang, MD\textsuperscript{a}, Xiaoying He, MB\textsuperscript{b}, Wei Wang, MB\textsuperscript{c}, Huanjiang Niu, MD\textsuperscript{d}, Yirong Wang, MM\textsuperscript{b}, Xiujun Cai, MD, PhD\textsuperscript{d}, Shuxu Yang, MD\textsuperscript{b}.

Abstract

\textbf{Introduction:} Neurosarcoidosis accounts for approximately 5\% of the sarcoidosis, which develops exclusively in the nervous system and is always difficult to diagnose. We describe a rare case of isolated neurosarcoidosis mimicking as multifocal meningiomas. A 27-year-old male was admitted to our hospital with a history of unconsciousness and convulsion 1 month ago, which was suspected as a seizure. The results showed no abnormalities in complete blood count; serum electrolytes; erythrocyte sedimentation rate and ultrasonography of the liver, pancreas, spleen, kidney and parotid gland, and so on. Chest radiograph and electroencephalogram were also normal. Serum-angiotensin-converting enzyme slightly increased. Normal opening pressure was shown in cerebrospinal fluid sampling, which includes 8/μL white blood cells, 0.93g/L protein, and 3.03 mmol/L glucose. Enhanced magnetic resonance imaging revealed multifocal enhancement lesions, including left sphenoid wing region, left temporal and bilateral occipitoparietal region, which were suspected as multiple “meningioma”. A left frontotemporal craniotomy was further performed. Both necrotizing and non-necrotizing granulomas were revealed in the pathological specimen, most of which were associated with multinucleated giant cells and macrophages. We could also see the fibrosis and inflammatory reaction in the sample composed of lymphocytes, histiocytes, and plasma cells. Histopathological examination showed that the cells were positive for human CD68 (KP1), CD68 (POM1), and CD163; however, they were negative for the AF, epithelial membrane antigen, and glial fibrillary acidic protein. Tuberculosis-deoxyribonucleic acid test and special stains for acid-fast bacilli and fungi were negative. The diagnosis was finally made as isolated neurosarcoidosis. Then the patient was treated with additional corticosteroid therapy. Serial imaging examination 4 months later revealed that the lesions extremely decreased.

\textbf{Conclusion:} The diagnosis of isolated central nervous system sarcoidosis was still difficult because of limitations of available diagnostic tests. So neurosarcoidosis in the clinical work should never be neglected.

\textbf{Abbreviations:} ACE = angiotensin-converting enzyme, CSF = cerebrospinal fluid, EEG = electroencephalogram, GFAP = glial fibrillary acidic protein, MRI = magnetic resonance imaging.

\textbf{Keywords:} diagnosis, neurosarcoidosis, treatment.

1. Introduction

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, usually diagnosed between 20 and 40 years of age.\textsuperscript{[1]} Neurosarcoidosis occurs in the central or peripheral nervous system and is usually associated with other sarcoidosis organ involvement. The prevalence of sarcoidosis is estimated at about 5 to 50 per 100,000, with the highest prevalence in northern Europe.\textsuperscript{[4]}

Neurosarcoidosis can mimic more common disease processes, such as meningioma, glioma, or metastases. Involvement of the nervous system is rare but can result in serious complications.\textsuperscript{[3]} Neurosarcoidosis is often suspected in patients with systemic sarcoidosis who develop neurological disorders.\textsuperscript{[4]} However, when sarcoidosis develops exclusively in the nervous system (isolated neurosarcoidosis), diagnosing neurosarcoidosis may be difficult because of the nonspecific clinical features.\textsuperscript{[3]} Furthermore, definite neurosarcoidosis requires histological confirmation, which is often not performed in patients with isolated central nervous system localization of sarcoidosis.

We present here an unusual case of isolated neurosarcoidosis manifesting as multiple meningiomas.

2. Clinical details

A 27-year-old male was admitted to our hospital with a history of unconsciousness and convulsion 1 month ago, which was
Figure 1. (A–D) Enhanced magnetic resonance imaging (MRI) revealed multifocal enhancement lesions, including left sphenoid wing region, left temporal and bilateral occipitoparietal region; (E–H) serial MRI 4 months later revealed extremely decreasing tumor size.

Figure 2. Histology of the pathological specimen reveals the presence of both necrotizing and non-necrotizing granulomas, many of which were associated with multinucleated giant cells and macrophages surrounded by fibrosis and an inflammatory reaction composed of lymphocytes, histiocytes, and plasma cells.
suspected as a seizure. The seizure that lasted for 30 seconds was generalized and tonic clonic, followed by loss of consciousness for about 15 minutes. Physical examination was normal. The results showed no abnormalities in complete blood count, serum electrolytes, erythrocyte sedimentation rate, and ultrasonography of the liver, pancreas, spleen, kidney, and parotid gland, and so on. Chest radiograph and EEG (electroencephalogram) were also normal. Serum-ACE (angiotensin-converting enzyme) slightly increased (48IU/L). Normal opening pressure was shown in CSF (cerebrospinal fluid) sampling, which includes 8/μL white blood cells, 0.93g/L protein, and 3.03mmol/L glucose. Enhanced MRI (magnetic resonance imaging) revealed multifocal enhancement lesions, including left sphenoid wing region, left temporal and bilateral occipitoparietal region, including the largest mass (1.5 x 1.5 x 3cm³), which were isointense on T1-weighted images, hyperintense on T2-weighted images, and enhanced homogenously, and were suspected as multiple “meningioma” (Fig. 1A–D). Then, we performed the left frontotemporal craniotomy. Both necrotizing and non-necrotizing granulomas (Fig. 2) were revealed in the pathological specimen, most of which were associated with multinucleated giant cells and macrophages (Fig. 2). We could also see the fibrosis and inflammatory reaction in the sample composed of lymphocytes, histiocytes, and plasma cells (Fig. 2). Histopathological examination showed that the cells were positive for human CD68 (KP1), CD68 (PGM1) (CD68 expresses in monocytes, macrophages, and epithelioid cells), and CD163 (a marker of sarcoidosis); however, they were negative for the AF (A), epithelial membrane antigen (E), and glial fibrillary acidic protein (G). Histopathological examination showed that the cells were positive for human CD68 (KP1) (A), CD68 (PGM1) (B), and CD163 (C); however, they were negative for AF (D), epithelial membrane antigen (E), and glial fibrillary acidic protein (F).

3. Discussion

Neurosarcoidosis is the neurologic manifestation of sarcoidosis, a granulomatous inflammatory disease, which although most often affects the lungs, can also affect the eyes, skin, liver, spleen, and nervous system. Nervous system involvement has been reported in 5% to 15% of patients and can involve any part of the nervous system, ranging from brain parenchyma, cranial nerves, to peripheral nerves.

Neurologic symptoms were reported to be the first clinical manifestation of neurosarcoidosis in more than half of the cases. The previous study has shown that limb sensory disturbance and other symptoms involving the peripheral nervous system were the major clinical presentation. Diagnostic evaluation of patients with suspected neurosarcoidosis usually includes imaging examination, laboratory tests, and histopathologic identification. Multiple white matter lesions followed by meningeal enhancement is always found in the MRI of the neurosarcoidosis patient. Gallium scintigraphy is reported by Marangoni et al for the use of diagnosis of probable sarcoidosis owing to high sensitivity of the test. A recent study suggests that fluorodeoxyglucose-positron emission tomography computed tomography could be applied as a valid alternative imaging test, for it leads to better uptake in central nervous system sites. The usefulness of CSF ACE levels for the diagnosis of neurosarcoidosis is controversial. CSF abnormalities in neurosarcoidosis are usually nonspecific and can also be found in multiple sclerosis, Guillain–Barre syndrome, Behcet disease, brain tumors, and neurodegenerative diseases. When no extraneural organ is identified as possibly being involved with sarcoidosis, biopsy of the lesion in CNS is needed for the last diagnosis.

CS therapy remains first-line treatment for neurosarcoidosis with second-line therapy being other immunosuppressive agents, such as azathioprine and methotrexate. For severe manifestations, steroids are started at 1mg/kg or as a pulse of methylprednisolone 1000mg/d for 3 days, followed by taper-
Neurosurgery is only advised when medications fail or intracranial pressure is extremely high, which threaten life. In our patient, enhanced MRI revealed multifocal enhancement lesions, including left sphenoid wing region, left temporal and bilateral occipitoparietal region, giving the appearance of multiple “meningioma”. Our patient’s serum ACE level slightly increased before the surgery and did not vary significantly postoperatively. Surgery was performed with a preoperative diagnosis of “meningioma”. The final diagnosis is made by the histopathological specimens which showed necrotizing, non-necrotizing granulomas, multinucleated giant cells, and macrophages. Long-term and high-dose CS therapy was instituted.

In conclusion, the diagnosis and management of neurosarcoidosis remain difficult because of limitations of available diagnostic tests. So, it is important to keep neurosarcoidosis in mind, both preoperatively and intraoperatively, which leads to the appropriate treatment. There is a need in the future for a multicentral prospective study in order to develop diagnostic and therapeutic standards of neurosarcoidosis.

References

[1] Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009;80:297–304.
[2] Hoitsma E, Faber CG, Drent M, et al. Neurosarcoïdisis: a clinical dilemma. Lancet Neurol 2004;3:397–407.
[3] Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoïdisis: presentations and management. Neurologist 2010;16:2–15.
[4] Stern BJ, Kramholz A, Johns C, et al. Sarcoïdosis and its neurological manifestations. Arch Neurol 1985;42:909–17.
[5] Leonhard SE, Fritz D, Efimov F, et al. Neurosarcoïdosis in a tertiary referral center: a cross-sectional cohort study. Medicine (Baltimore) 2016;95:e3277.
[6] Ahn SW, Kim KT, Youn YC, et al. Isolated spinal cord neurosarcoïdosis diagnosed by cord biopsy and thalidomide trial. J Korean Med Sci 2011;26:154–7.
[7] James DC, Sharma OP. Neurosarcoïdosis. Proc R Soc Med 1967;60:1169–70.
[8] Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoïdosis in the 21st century. Curr Opin Pulm Med 2010;16:472–9.
[9] Chapelon C, Ziza JM, Piette JC, et al. Neurosarcoïdosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990;69:261–76.
[10] Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoïdosis. Sarcoïdosis Vasc Diffuse Lung Dis 2003;20:118–25.
[11] Wegener S, Linnebank M, Martin R, et al. Clinically isolated neurosarcoïdosis: a recommended diagnostic path. Eur Neurol 2015;73:71–7.
[12] Nozaki K, Scott TF, Sohn M, et al. Isolated neurosarcoïdosis: case series in 2 sarcoïdosis centers. Neurologist 2012;18:373–7.
[13] Pawate S, Moses H, Stram S. Presentations and outcomes of neurosarcoïdosis: a study of 54 cases. QJM 2009;102:449–60.
[14] Marangoni S, Argentierno V, Tavolato B. Neurosarcoïdosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol 2006;253:488–95.
[15] Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoïdosis. J Nucl Med 2006;47:1571–6.
[16] Sharma OP. Neurosarcoïdosis: a personal perspective based on the study of 37 patients. Chest 1997;112:220–8.
[17] Dutra LAI, Braga-Neto P, Oliveira RA, et al. Neurosarcoïdosis: guidance for the general neurologist. Arq Neuropsiquiatr 2012;70:293–9.